指南与共识中枢神经肿瘤放疗

基于更新版放射治疗肿瘤学组/国家研究组与欧洲癌症研究与治疗组织指南的不同靶区勾画在3-4级胶质瘤患者放疗中的毒性与疗效:一项随机对照临床试验

Toxicity and Efficacy of Different Target Volume Delineations of Radiation Therapy Based on the Updated Radiation Therapy Oncology Group/National Research Group and European Organization for Research and Treatment of Cancer Guidelines in Patients With Grade 3-4 Glioma: A Randomized Controlled Clinical Trial.
指南 / 共识 · Int J Radiat Oncol Biol Phys · 2024-11-28

该随机对照试验纳入245例新诊断WHO 3-4级胶质瘤患者,按1:1随机接受术后放疗联合同期及维持替莫唑胺化疗,分别采用更新版RTOG/NRG指南(n=122)或EORTC指南(n=123)勾画靶区。两组低级别或高级别毒性均无差异,均无5级毒性,神经毒性无显著差异;中位PFS分别为11.0个月与10.0个月(P=.73),中位OS分别为19.5个月与18.5个月(P=.80)。在IDH野生型胶质母细胞瘤亚组中,两组中位PFS和OS亦无显著差异。

要点

  • 两组低级别或高级别毒性均无差异,均未出现5级毒性
  • RTOG/NRG组与EORTC组中位PFS分别为11.0个月与10.0个月,差异无统计学意义(P=.73)
  • RTOG/NRG组与EORTC组中位OS分别为19.5个月与18.5个月,差异无统计学意义(P=.80)

核心结论

  • 与EORTC原则相比,按照RTOG/NRG原则进行术后放疗未增加治疗相关毒性,且对3-4级胶质瘤患者疗效相当,包括IDH野生型胶质母细胞瘤亚组。

研究设计与样本

  • 随机对照临床试验,纳入245例新诊断WHO 3-4级胶质瘤患者,按1:1随机分配接受术后放疗联合同期及维持替莫唑胺化疗。
  • 放疗靶区勾画分别采用更新版RTOG/NRG指南(n=122)或EORTC指南(n=123)。
  • 主要终点为治疗相关毒性,PFS和OS为次要终点。

主要发现

  • 两组低级别或高级别毒性均无差异,两组均未出现5级毒性,RTOG/NRG组与EORTC组神经毒性无显著差异。
  • RTOG/NRG组与EORTC组中位PFS分别为11.0个月(95%CI 7.1-14.9个月)与10.0个月(95%CI 3.8-16.2个月),P=.73。
  • RTOG/NRG组与EORTC组中位OS分别为19.5个月(95%CI 14.2-24.8个月)与18.5个月(95%CI 12.8-24.2个月),P=.80。
  • 在IDH野生型胶质母细胞瘤患者中,RTOG/NRG组与EORTC组中位PFS分别为8.0个月(95%CI 6.8-9.2个月)与8.0个月(95%CI 7.0-9.0个月),P=.38。
  • 在IDH野生型胶质母细胞瘤患者中,RTOG/NRG组与EORTC组中位OS分别为12.0个月(95%CI 7.2-16.8个月)与11.0个月(95%CI 9.7-12.3个月),P=.10。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our study aimed to evaluate the safety and efficacy of radiation therapy (RT) in the treatment of grade 3-4 glioma by comparing the updated Radiation Therapy Oncology Group (RTOG)/National Research Group (NRG) with European Organization for Research and Treatment of Cancer (EORTC) guidelines for target volume delineation. METHODS AND MATERIALS: A total of 245 patients with newly diagnosed World Health Organization grade 3-4 glioma were enrolled and randomly assigned (1:1 ratio) to undergo postoperative RT with concurrent and maintenance temozolomide. The radiation target volume delineation was determined by using either the updated RTOG/NRG (n = 122) or EORTC guidelines (n = 123). The primary endpoint was the toxicity associated with treatment. Progression-free survival (PFS) and overall survival (OS) were considered secondary endpoints. RESULTS: No differences in low- or high-grade toxicities between the 2 groups, and neither group exhibited grade 5 toxicities. No significant differences in neurologic toxicities were observed between the RTOG/NRG and EORTC groups. The median PFS in the RTOG/NRG group and the EORTC group was 11.0 months (95% confidence interval [CI], 7.1-14.9 months) and 10.0 months (95% CI, 3.8-16.2 months), respectively (P = .73). The median OS in the RTOG/NRG group and the EORTC group was 19.5 months (95% CI, 14.2-24.8 months) and 18.5 months (95% CI, 12.8-24.2 months), respectively (P = .80). In patients with isocitrate dehydrogenase wild-type glioblastoma, there were no significant differences between the RTOG/NRG group and the EORTC group in median PFS (8.0 months [95% CI, 6.8-9.2 months] vs. 8.0 months [95% CI, 7.0-9.0 months], P = .38) and median OS (12.0 months [95% CI, 7.2-16.8 months] vs. 11.0 months [95% CI, 9.7-12.3 months], P = .10). CONCLUSIONS: Compared with EORTC principles, postoperative RT according to RTOG/NRG principles did not increase treatment-related toxicities and was equally effective for patients with grade 3-4 glioma, including the subgroup of patients with isocitrate dehydrogenase wild-type glioblastoma.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Qiu Y, Li Y, Jiang C, et al. Toxicity and Efficacy of Different Target Volume Delineations of Radiation Therapy Based on the Updated Radiation Therapy Oncology Group/National Research Group and European Organization for Research and Treatment of Cancer Guidelines in Patients With Grade 3-4 Glioma: A Randomized Controlled Clinical Trial. Int J Radiat Oncol Biol Phys. 2024. PMID: 39615657. doi:10.1016/j.ijrobp.2024.11.094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。